Baird Financial Group
HRMY icon

Baird Financial Group’s Harmony Biosciences HRMY Stock Holding History

Baird Financial Group’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$205K Buy
+5,638
New +$178K ﹤0.01% 1870

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Baird Financial Group's HRMY Position: Q2 2026 in Review

Baird Financial Group opened a new position in Harmony Biosciences (HRMY) in Q2 2026: 5,638 shares worth $205K. The stake represents ﹤0.01% of the portfolio and ranks #1870 among its holdings.

326 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • Baird Financial Group held 5,638 shares of Harmony Biosciences worth $205K as of Q2 2026.
  • Harmony Biosciences was a new Baird Financial Group position in Q2 2026.
  • Harmony Biosciences made up ﹤0.01% of Baird Financial Group's portfolio in Q2 2026, its #1870 holding.
  • 326 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Baird Financial Group's 13F filing for Q2 2026, filed 12 Aug 2026.